CDR-Life Inc.’s Post

Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at American Society of Clinical Oncology (ASCO) 2024 Albert Bourla Pfizer #ASCO24 #Cancer #LCSM #NSCLC #ClinicalTrials #OncoDaily #Oncology

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer.TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer.Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy

Congratulations to Takeda Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than a Decade FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free Survival, Versus Placebo Plus Best Supportive Care in Two Phase 3 Clinical Trials FRUZAQLA Demonstrated a Manageable Safety Profile in Previously Treated Patients with mCRC Across Both Trials https://lnkd.in/gjZrh3Ed

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

Exciting news in the world of cancer treatment! The phase 2b KEYNOTE-942 trial has shown that combining Moderna's personalized mRNA-4157 cancer vaccine with Merck's pembrolizumab (Keytruda) significantly improves outcomes for high-risk melanoma patients. This combination therapy reduced the risk of recurrence or death by an impressive 44%, and patients experienced a meaningful improvement in recurrence-free and distant metastasis-free survival. The FDA has granted this combination Breakthrough Therapy Designation, and further phase 3 trials are underway. #Healthcare #mRNA #Melanoma #CancerResearch #ClinicalTrials

This post is intended for a US audience:   Today we announced the US FDA granted Priority Review for our HER2-directed antibody drug conjugate (ADC) – which we develop in collaboration with Daiichi Sankyo – for the potential treatment of certain patients with metastatic HER2-positive solid tumors.   HER2-directed therapies have been used for decades in breast cancer, where they have transformed outcomes for patients. Only recently has HER2 emerged as a treatment target for other types of solid tumors, creating an opportunity for us to address an important unmet need in patients. If approved, our ADC would potentially be the first HER2-directed treatment to receive a tumor-agnostic indication, aiding in our mission to redefine cancer care. Learn more about the news: https://lnkd.in/e_8Rajn3 #USOnly #AstraZenecaUS

The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer, reiterating the need for a more accurate population selection in clinical trials. Read Viewpoint in #Med. https://lnkd.in/eEK5VPMV #lungcancer #clinicaltrial #tiragolumab #TIGIT #SKYSCRAPER-02

🚀 Exciting Developments in NSCLC Treatment! 🚀 The landscape of Non-Small Cell Lung Cancer (NSCLC) treatment is evolving rapidly with new targets and therapies making significant strides. Here are some of the top targets gaining attention: Stay tuned for more updates and breakthroughs in NSCLC treatment. #LungCancer #NSCLC #CancerResearch #Oncology #Pharma #TargetedTherapies #CancerTreatment

Not quite the outcome they hoped for. Sanofi's development program for ADC tusamitamab ravtansine comes to a close for not achieving a primary endpoint in a P3 lung cancer study. https://lnkd.in/eE_TAiuu #Sanofi #ImmunoGen #LungCancer #NSCLC #AntibodyDrugConjugate #ADC #Pharma #Healthcare #PharmaInnovation #Docetaxel